Mamidipudi Thirumala Krishna, Saibal Moitra, Anna Freeman, Ben Ainsworth, Rebecca Knibb, Ramesh Kurukulaaratchy, Adel H. Mansur
{"title":"Asthma and Multimorbidity Amongst Ethnic Minority Groups in High Income Countries","authors":"Mamidipudi Thirumala Krishna, Saibal Moitra, Anna Freeman, Ben Ainsworth, Rebecca Knibb, Ramesh Kurukulaaratchy, Adel H. Mansur","doi":"10.1111/cea.70329","DOIUrl":"10.1111/cea.70329","url":null,"abstract":"<p>Asthma is one of the commonest noncommunicable diseases worldwide. Poor clinical outcomes have been reported in asthma amongst ethnic minority groups (EMGs) and reasons are likely to be multifactorial. There is a suggestion that underlying disease may behave differently amongst EMGs, alongside other factors including deprivation, cultural, religious, social, literacy, patient beliefs, healthcare access, treatment adherence, alongside greater burden of multimorbidity. Multimorbidity (presence of ≥ 2 long-term health conditions) in asthma is increasingly known to contribute to greater asthma burden, with differences in multimorbidity burden and patterns seen across ethnicities with a tight association with deprivation. Earlier onset of multimorbidity with relatively reduced survival has been reported amongst EMG patients, particularly those from a deprived background compared to White patients. Data regarding asthma, multimorbidity and ethnicity are scant, but emerging data suggest that multimorbidity is heterogenous, and that ethnic background is associated with variations in asthma outcomes and multimorbidity phenotypes. What is currently lacking is population-based research with a joined-up interrogation of primary care and secondary care databases to determine the prevalence and patterns of T2 and non T2 multimorbidity in asthma amongst EMGs, and analysis of patterns of associations and link to socio-demographic variables and clinical outcomes. Deeper insight into views of EMG patients and their carers regarding lived experiences of asthma and multimorbidity management, as well as those of healthcare professionals is needed, to allow development of culturally tailored resources. These studies are likely to shape a holistic culturally tailored multidimensional and an equitable approach to management of asthma with multimorbidity amongst EMGs.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1031-1047"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luis García-Marcos, Chen-Yuan Chiang, M. Innes Asher, Guy B. Marks, Asma El Sony, Refiloe Masekela, Karen Bissell, Eamon Ellwood, Philippa Ellwood, Neil Pearce, David P. Strachan, A. Elena Martínez-Torres, Manuel Sánchez-Solís, Kevin Mortimer, Eva Morales, The Global Asthma Network Phase I Study Group
{"title":"Worldwide Impact of Human Development and Inequality on the Prevalence of Asthma, Rhinoconjunctivitis and Eczema. Global Asthma Network's Ecological Study","authors":"Luis García-Marcos, Chen-Yuan Chiang, M. Innes Asher, Guy B. Marks, Asma El Sony, Refiloe Masekela, Karen Bissell, Eamon Ellwood, Philippa Ellwood, Neil Pearce, David P. Strachan, A. Elena Martínez-Torres, Manuel Sánchez-Solís, Kevin Mortimer, Eva Morales, The Global Asthma Network Phase I Study Group","doi":"10.1111/cea.70355","DOIUrl":"10.1111/cea.70355","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lower-income countries have lower asthma prevalence. However, how differences in human development and inequality can explain changes in the prevalence of asthma and allergic diseases is not known.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Global Asthma Network Phase I study reported prevalence of asthma and allergic diseases in children (6–7 years), adolescents (13–14 years), and their parents/guardians in 16, 25 and 17 countries. Gini inequality index (GinI) and human development index (HDI), together with mean annual relative humidity and temperature, and latitude, were used as potential explanatory factors of prevalence differences using meta-regression models, fitted values and heatmaps of prevalence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>GinI and HDI explained some proportion of asthma prevalence variability, which was highest in children (up to ~70% for disease indicators such as current wheeze or symptoms of severe asthma) and lowest in adolescents (~22% for symptoms of severe asthma or asthma ever). Rhinoconjunctivitis prevalence variability was poorly explained by covariates (from ~53% for current rhinoconjunctivitis among children—an exception—to none). Eczema indicators were explained in a range from ~60% in children (current eczema symptoms and symptoms of severe eczema) to ~12% in adolescents (current eczema symptoms). Overall, heatmaps showed areas of higher prevalence in the intersection of high GinI and high HDI values.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HDI and Gini explain part of the worldwide variability in the prevalence of asthma, rhinoconjunctivitis, and eczema. This explanatory power is highest for asthma and lowest for rhinoconjunctivitis. Lower-resourced communities in highly developed countries show the greatest hazard, particularly for asthma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1048-1062"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70355","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148162031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anna Nilson, Patricia Couroux, Jaana Haka, Silja Halme, Pekka Mattila, R J Joost van Neerven, Rolien Pels-Rijcken, Janneke Ruinemans-Koerts, Yvonne Schmidt-Hieltjes, Anne Marie Salapatek, Kati Sallinen, Kristiina Takkinen, Daphne Tsitoura, Dirk-Jan Opstelten, Juha Rouvinen
{"title":"Subcutaneous Allergen Immunotherapy With Thermosensitive Hydrogel and Recombinant Birch Pollen Allergen Variant, a Randomised Controlled Trial.","authors":"Anna Nilson, Patricia Couroux, Jaana Haka, Silja Halme, Pekka Mattila, R J Joost van Neerven, Rolien Pels-Rijcken, Janneke Ruinemans-Koerts, Yvonne Schmidt-Hieltjes, Anne Marie Salapatek, Kati Sallinen, Kristiina Takkinen, Daphne Tsitoura, Dirk-Jan Opstelten, Juha Rouvinen","doi":"10.1111/cea.70424","DOIUrl":"https://doi.org/10.1111/cea.70424","url":null,"abstract":"<p><strong>Background: </strong>This paper reports a Phase 1, randomised, placebo-controlled, dose-escalation trial (NCT06037148) with DM-101PX that contains a recombinant hypoallergenic Bet v 1 variant formulated with thermosensitive hydrogel. The objectives of the study included assessment of treatment-related adverse events and the number of participants reaching the maximum dose. In addition, Bet v 1-specific immunoglobulins were analysed to explore the immunological effects of treatment. The trial was funded by Desentum Oy.</p><p><strong>Methods: </strong>The study included three cohorts differing in starting and maximum dose. Per cohort, subjects were randomised (4:1) to receive 10 weekly subcutaneous injections with DM-101PX or placebo. Main inclusion criteria comprised adult subjects with a birch pollen allergy for ≥ 2 years, positive skin prick test, birch pollen-IgE ≥ 0.7 kU/L and symptoms upon exposure to birch pollen. The randomisation schedule was generated using software. During the trial, the investigator, clinic staff, participants and sponsor remained blinded to the treatment groups. The primary endpoint was the occurrence of treatment emergent adverse events and adverse events of special interest.</p><p><strong>Results: </strong>In each cohort, 10 subjects were randomised and all were used for analysis of safety data. Treatment-related adverse events were reported by 22/24 (91.7%) DM-101PX treated subjects and by 5/6 (83.3%) placebo-treated subjects, which were only of mild or moderate intensity. The DM-101PX and placebo-treated subjects had mainly local injection site reactions, 138/153 (90.2%) and 22/24 (91.2%), respectively. Fifteen systemic allergic reactions were reported by 5/24 (20.8%) DM-101PX-treated subjects, and 2 systemic allergic reactions were reported by 1/6 (16.7%) placebo-treated subject, all of which were of Grade 1. 21/24 (88%) of subjects reached the maximum dose. Treatment with DM-101PX induced pronounced levels of Bet v 1-specific IgG<sub>4</sub> and post-treatment sera effectively blocked basophil activation.</p><p><strong>Conclusions: </strong>This small study demonstrated that DM-101PX was generally well tolerated and induced a strong and functional immune response.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christy Wing Man Leung, Nam Sze Cheng, Ting Fan Leung
{"title":"Oral Immunotherapy for Food-Allergic Patients: Real-World Barriers.","authors":"Christy Wing Man Leung, Nam Sze Cheng, Ting Fan Leung","doi":"10.1111/cea.70425","DOIUrl":"https://doi.org/10.1111/cea.70425","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chang Yong Wang, Ji Wang, Peng Gao, Wei Jie Zhang, Min Xie, Gang Liu, Ling Qin, Zhi Hong Chen, Dan Liu, Jie Zhang, Feng Ming Luo, Wei Min Li, Gang Wang, Lisa G Wood
{"title":"Sitting Time and Physical Activity Correlate With Asthma Exacerbations in Adults: A Cross-Sectional Study From the Australasian Severe Asthma Network.","authors":"Chang Yong Wang, Ji Wang, Peng Gao, Wei Jie Zhang, Min Xie, Gang Liu, Ling Qin, Zhi Hong Chen, Dan Liu, Jie Zhang, Feng Ming Luo, Wei Min Li, Gang Wang, Lisa G Wood","doi":"10.1111/cea.70421","DOIUrl":"https://doi.org/10.1111/cea.70421","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yue Zhang, Jia Su, Lin Zhong, Zhuokun Ran, Huiyin Wan, Xiyuan Zhou
{"title":"Dupilumab Remodels the Skin and Gut Microbiomes in Children With Moderate-To-Severe Atopic Dermatitis: A Pilot Longitudinal Study.","authors":"Yue Zhang, Jia Su, Lin Zhong, Zhuokun Ran, Huiyin Wan, Xiyuan Zhou","doi":"10.1111/cea.70417","DOIUrl":"https://doi.org/10.1111/cea.70417","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}